Year-over-year earnings per share growth for the last twelve months: krystalbio.com (KRYS)

Brandmark of Krystal Biotech (KRYS)

Krystal Biotech, Inc. (KRYS) is a leading pioneer in skin gene therapy with colossal investments in unique drug delivery methods. The GURU.Markets system generates this chart, where the amplitude of quarterly EPS fluctuations demonstrates that the -23.20 level is the current value. The company's flawless image relies on the trust of patients with rare pathologies, yet its financial stability is based primarily on sales of the drug Vyjuvek.

Krystal Biotech (KRYS) Quarterly EPS earnings growth: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for Krystal Biotech, Inc.

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Analysis of all company metrics:Krystal Biotech, KRYS
Finished products of Krystal Biotech, Inc.

Quarterly EPS growth reflects the dynamics of net income per share relative to the same period last year. This metric allows a value investor to identify undervalued assets with a high margin of safety. For Krystal Biotech, Inc. (KRYS), this indicator confirms the effectiveness of commercializing its gene delivery platform for treating dermatological pathologies. By analyzing the quarterly EPS increase, one can assess the scalability of the business model, which serves as a safeguard against purchasing overvalued securities at the peak of the cycle.

Competitor analysis for Krystal Biotech, Inc.

APGE: Quarterly EPS earnings growth|ARQT - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Vericel|Year-over-year earnings per share growth for the last 12 months ORKA (orukatx.com)|Year-over-year earnings per share growth for the last twelve months Sanara (SMTI)|DBV Technologies - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Solesence SLSN|journeymedicalcorp.com (DERM) - Earnings per share growth in annualized terms for the last twelve months|FBRX - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months EMPG|SLGL (sol-gel.com) - Year-over-year net earnings per share growth for the last 12 months|AXIL (AXIL Brands, Inc.) - Year-over-year earnings per share growth for the last twelve months|MDCX (Medicus Pharma Corp) - Quarterly EPS earnings growth|Verrica Pharmaceuticals (VRCA) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HOTH (Hoth Therapeutics, Inc.)|BFRI - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth VYNE (VYNE Therapeutics)|Year-over-year earnings per one share growth for the last 12 months SNOA|Quoin Pharmaceuticals Ltd. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Azitra Corporation AZTR|DRMA (Dermata) - Year-over-year net earnings per share growth for the last 12 months|Elevai Labs Inc. (ELAB) - Quarterly EPS earnings growth|RVNC (Revance Therapeutics, Inc.) - Quarterly EPS earnings growth